No stem cell-derived aesthetic product has FDA approval as a drug. Exosomes, fibroblasts, and placental extracts used cosmetically typically fall outside drug regulation in most countries, marketed instead as cosmeceuticals or medical devices under lighter regulatory pathways. The EU has not approved any cell-derived aesthetic therapy as a medicinal product. This regulatory gap means quality assurance, purity, and efficacy labelling are inconsistent between suppliers.
Aesthetic treatments using stem cell derivatives—primarily exosomes and umbilical-cord fibroblasts—target skin ageing at the cellular level. Exosomes, tiny vesicles naturally released by stem cells, carry proteins and genetic material that may stimulate collagen production and improve skin texture. Umbilical-cord fibroblasts, harvested from donated umbilical tissue, are specialised cells responsible for maintaining skin structure in developing tissue. Placental extracts contain growth factors accumulated during foetal development. These cell-derived materials are investigated for reducing fine lines, improving elasticity, and enhancing overall skin luminosity. Unlike ablative procedures, they work by encouraging the skin's own repair mechanisms rather than removing tissue. Clinical interest has grown steadily, with 9 registered trials globally examining safety and efficacy across different age groups and skin types.
Am I a candidate? → · Aesthetic & Anti-Ageing: full overview → · Aesthetic & Anti-Ageing cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită